In recent years, the demand for medical devices has been rising, and there is an increasingly wide market in the pharmaceutical industry. However, due to the long-term emphasis on the use of imported equipment by medical institutions, coupled with lax supervision and other reasons, some domestic high-end medical devices have suffered discrimination. It is difficult to expand the domestic market. In the past two years, China's medical device market has grown at a rate of 25%, far exceeding the growth rate of 7% in the international medical device market. Comparing the output ratio of medical devices and pharmaceutical products 1:6 to the output ratio of 1:1 in the international market, the potential of the Chinese market is considerable. However, overseas companies are more dominant in this industry than in China, and domestic companies are hindered by many factors. Its constraints are not only derived from the strength of manufacturing technology, but also subject to the many sequelae left in the domestic market by the long-term "market-for-technology" model. The hospital is a large-scale use of medical device products, and the current number of imported hospitals in the domestic hospital rating and approval is listed as one item, which is one of the inspection projects for hospital grade. This "overlord clause" directly suppresses the development space of domestic excellent manufacturing enterprises, and the situation of "no price, no market, no technology and no market" is prominent. If China's local manufacturing industry has to endure the erosion of high-quality imported products, the unreasonable system is the self-restraint of the Chinese market. The irrational system is also reflected in the fact that hospitals can discount expensive imported products. The medical equipment purchased by the hospital belongs to the scope of medical insurance reimbursement, the imported products are the key items of medical insurance reimbursement, and the high rebate of imported products is no longer a secret, thus breeding a “hotbed†for imported products. Even a small number of hospitals have named all the imported products on the equipment purchase book. Under the circumstance that the technology is still not mature and the market is tilted, the operation status of domestic medical device manufacturers is even more difficult. Faced with such a good development prospect of medical devices, foreign companies are eyeing this fat. Domestic enterprises should seize the opportunity to develop and strengthen the market share of domestically produced devices, and should not be seized by foreign companies.
We are manufacturer of Skin Whitening in China, if you want to buy Kojic Acid Dipalmitate Powder,Ethyl Ascorbyl Powder,Tranexamic Acid Powder please contact us.
Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
Skin Whitening Powder,Hexapeptide-2 Peptide Powder,Phenylethyl Resorcinol Powder,Cyclotetrasiloxane Octamethyl Powder Xi'an Henrikang Biotech Co.,Ltd , https://www.henruikangbio.com
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.